Avigen announces corporate restructuring
As a result of the restructuring, which will involve staff reductions of over 70% of the company’s total workforce, Avigen expects to have sufficient cash to fund operations
Tolerance Bio has signed an agreement securing an exclusive licence from Tanabe Pharma for TLB-33, a clinical-stage anti-IL-33 monoclonal antibody, in a deal that includes potential development and sales milestone payments of up to around $560m.